THE CHARACTERISATION OF RISK FACTORS, SUBSTRATE AND MANAGEMENT STRATEGIES FOR ATRIAL FIBRILLATION

Geetanjali Rangnekar

BSc (Honours)

Centre for Heart Rhythm Disorders

School of Medicine

The University of Adelaide

A thesis submitted to The University of Adelaide in fulfilment of the requirements of the degree of

Doctor of Philosophy

August 2014
To my parents, Abhay and Suniti

To my sister and brother in law, Devyani and Harshit

In loving memory of my grandparents
TABLE OF CONTENTS

ABSTRACT .................................................................................................................. 17

DECLARATION .......................................................................................................... 19

ACKNOWLEDGEMENTS .......................................................................................... 20

COMMUNICATIONS TO LEARNED SOCIETIES .................................................. 21

PRIZES AND AWARDS DURING CANDIDATURE ............................................ 24

CHAPTER ONE ......................................................................................................... 25

LITERATURE REVIEW .............................................................................................. 25

1.1 INTRODUCTION .................................................................................................. 25

1.1.1 The Risk Factors Associated with Atrial Fibrillation ..................................... 26

1.1.1.1 Conventional Risk Factors Associated with Atrial Fibrillation ...................... 27

1.1.1.1.1 Advancing Age ............................................................................................ 27

1.1.1.1.2 Gender ........................................................................................................ 28

1.1.1.1.3 Hypertension (HT) ..................................................................................... 29

1.1.1.1.4 Left Ventricular Hypertrophy (LVH) ........................................................ 31

1.1.1.1.5 Congestive Heart Failure (CHF) ............................................................... 32

1.1.1.1.6 Coronary Artery Disease (CAD) ............................................................... 33

1.1.1.1.7 Myocardial Infarction (MI) ........................................................................ 34

1.1.1.1.8 Diabetes Mellitus (DM) .............................................................................. 35

1.1.1.1.9 Congenital Heart Disease (CHD) .............................................................. 36

1.1.1.1.10 Valvular Heart Disease (VHD) ............................................................... 37
1.1.1.11 Cigarette Smoking

1.1.1.12 Alcohol Consumption

1.1.2 New Risk Factors Associated with Atrial Fibrillation

1.1.2.1 Obesity

1.1.2.2 Obstructive Sleep Apnoea (OSA)

1.1.2.3 Aortic Stiffness

1.1.2.4 Familial Atrial Fibrillation

1.1.3 Summary

1.2 Characterization of the Substrate Associated with New Onset Atrial Fibrillation

1.2.1 Definition of New Onset Atrial Fibrillation

1.2.2 Management of New Atrial Fibrillation

1.2.3 Mechanisms of Atrial Fibrillation

1.2.4 Non Invasive Characterisation of Substrate Associated with Atrial Fibrillation

1.2.5 Summary

1.3 Consequences of Atrial Fibrillation

1.3.1 Economic Burden of Atrial Fibrillation
1.3.2 Hospital Burden of Atrial Fibrillation ...................................................... 56

1.3.2.1 Trends in Elective Admissions for Atrial Fibrillation ........................................ 58
1.3.2.2 Trends in Emergency Department Admissions for Atrial Fibrillation ............ 60

1.3.3 Atrial Fibrillation Rehospitalisations ...................................................... 61

1.3.4 Summary ................................................................................................. 63

1.3.5 Thromboembolic Risk Associated with Atrial Fibrillation ......................... 64

1.3.5.1 Abnormalities in the Atrial and Vessel Wall .............................................. 65
1.3.5.2 Abnormalities in the Blood Flow ............................................................ 66
1.3.5.3 Abnormalities in the Blood Constituents .................................................. 67

1.3.6 Bio-markers of Thrombogenesis in Atrial Fibrillation .............................. 69

1.3.6.1 CRP and IL-6 .......................................................................................... 69
1.3.6.2 Asymmetric Dimethyl Arginine (ADMA) ............................................... 71
1.3.6.3 Endothelin-1 (ET-1) ................................................................................. 73
1.3.6.4 CD40 Ligand (CD40L) ............................................................................. 74
1.3.6.5 Cell Adhesion Molecules ....................................................................... 75
1.3.6.6 Extracellular Matrix (ECM) Remodelling Proteins .................................. 76
1.3.6.7 Myeloperoxidase (MPO) ......................................................................... 77

1.3.7 Summary ................................................................................................... 78

1.4 Tertiary Care Management Strategies for Atrial Fibrillation ....................... 79

1.4.1 Rate Control Versus Rhythm Control Trials ............................................. 80

1.4.2 Rate Control Strategies ........................................................................... 81

1.4.3 Rhythm Control Strategies ...................................................................... 83

1.4.3.1 Pharmacological Interventions .................................................................. 83
INDEPENDENT RISK FACTORS FOR THE DEVELOPMENT OF NON-
VALVULAR ATRIAL FIBRILLATION: A SYSTEMATIC LITERATURE REVIEW
AND META-ANALYSIS ................................................................. 89

2.1 INTRODUCTION........................................................................... 89

2.2 METHODS .................................................................................. 90

2.2.1 Search Strategy......................................................................... 90

2.2.2 Risk Factors Examined............................................................. 91

2.2.3 Statistical Analysis................................................................... 92

2.3 RESULTS .................................................................................... 93

2.3.1 Study Characteristics............................................................... 93

2.3.2 Independent Predictors of Atrial Fibrillation............................ 93

2.3.2.1 Chronic Heart Failure (CHF)................................................ 94

2.3.2.2 Gender ............................................................................... 94

2.3.2.3 Coronary Artery Disease (CAD) ............................................ 94

2.3.2.4 Hypertension (HT)................................................................. 95

2.3.2.5 Left Ventricular Hypertrophy (LVH)...................................... 95

2.3.2.6 Diabetes Mellitus (DM) ......................................................... 95

2.3.2.7 Advancing Age................................................................. 96

2.3.2.8 Body Mass Index (BMI) ....................................................... 96

2.3.2.9 Alcohol Consumption (AC)................................................ 96
2.3.2.10 Cigarette Smoking (CS) ................................................................. 97

2.3.3 Population Attributable Risk (PAR) .................................................. 97

2.5 DISCUSSION ......................................................................................... 97

2.5.1 Chronic Heart Failure ................................................................. 98

2.5.2 Hypertension ................................................................................. 99

2.5.3 Metabolic Syndrome (Diabetes Mellitus and Obesity) ................ 100

2.5.4 Demographics (Aging and Gender) ............................................. 101

2.5.5 Non-predictors of Atrial Fibrillation Development ................. 102

2.6 CLINICAL IMPLICATIONS ................................................................. 103

2.7 LIMITATIONS ................................................................................ 103

2.8 CONCLUSIONS .............................................................................. 104

2.9 FIGURES ......................................................................................... 106

FIGURE 1 STUDY SEARCH CRITERIA .................................................. 106

FIGURE 2 UNIVARIATE ANALYSES RESULTS FOR ALL RISK FACTORS. 107

FIGURE 3 MULTIVARIATE ANALYSES RESULTS FOR ALL RISK FACTORS. 108

2.10 TABLES ......................................................................................... 109

TABLE 1 STUDY CHARACTERISTICS AND BASELINE CHARACTERISTICS OF THE STUDY PARTICIPANTS 109

TABLE 2 CONGESTIVE HEART FAILURE ............................................. 112

TABLE 3 MALE GENDER ....................................................................... 115

TABLE 4 CORONARY ARTERY DISEASE ............................................. 117

TABLE 5 HYPERTENSION ..................................................................... 121

TABLE 6 LEFT VENTRICULAR HYPERTROPHY .................................. 126
TABLE 7 DIABETES MELLITUS ......................................................... 130
TABLE 8 AGE ........................................................................... 135
TABLE 9 BODY MASS INDEX .......................................................... 139
TABLE 10 ALCOHOL CONSUMPTION .......................................... 143
TABLE 11 CIGARETTE SMOKING ..................................................... 145
TABLE 12 WEIGHTS OF EACH STUDY IN EACH UNADJUSTED AND ADJUSTED ANALYSIS ............... 147
TABLE 13 POPULATION ATTRIBUTABLE RISK FOR MODIFIABLE RISK FACTORS ............................ 149

CHAPTER THREE ........................................................................ 150

CHARACTERISATION OF THE STRUCTURAL AND ELECTRICAL
REMODELLING ASSOCIATED WITH NEW ONSET ATRIAL FIBRILLATION

3.1 INTRODUCTION........................................................................ 150
3.2 METHODS ............................................................................. 151
   3.2.1 Recruitment of Newly Diagnosed Atrial Fibrillation Patients .......... 151
   3.2.2 Recruitment of Age-matched Controls ...................................... 152
   3.2.3 Structured Clinical Interview .................................................. 153
   3.2.4 Structural Substrate Assessment ............................................. 153
   3.2.5 Electrical Substrate Assessment .............................................. 154
   3.2.6 Statistics ........................................................................... 155
3.3 RESULTS ............................................................................... 156
   3.3.1 Baseline Characteristics of Controls vs AF Patients .................... 156
   3.3.2 Baseline Characteristics of PAF vs PerAF Patients ...................... 156
3.3.3  **Structural Substrate Assessment** .......................................................... 157

3.3.3.1 Left Atrial Longitudinal Axis ................................................................. 157

3.3.3.2 Left Atrial Transverse Axis ................................................................. 157

3.3.3.3 Left Atrial Area ..................................................................................... 158

3.3.3.4 Left Atrial Volume ............................................................................... 158

3.3.3.5 Left Ventricular Hypertrophy: Interventricular Septal Diameter (IVSd) ............ 158

3.3.3.6 Left Ventricular Ejection Fraction (LVEF) .................................................. 159

3.3.3.7 Mitral E Velocity .................................................................................. 159

3.3.3.8 Mitral A Velocity .................................................................................. 159

3.3.3.9 E/A Ratio ............................................................................................ 159

3.3.3.10 Pulmonary Vein S/D Ratio ..................................................................... 159

3.3.3.11 Pulmonary Vein Septal E’ ..................................................................... 160

3.3.4  **Electrical Substrate** ............................................................................... 160

3.3.4.1 Atrial Ectopy Burden and Relative Earliness .............................................. 160

3.4  **DISCUSSION** .......................................................................................... 160

3.4.1  **Substrate in New Paroxysmal AF** ......................................................... 161

3.4.2  **Substrate in New Persistent AF** ............................................................. 162

3.5  **CLINICAL IMPLICATIONS** ...................................................................... 164

3.6  **LIMITATIONS** ........................................................................................ 165

3.7  **CONCLUSIONS** ....................................................................................... 166

3.8  **FIGURES** .................................................................................................. 167

**FIGURE 1 RECRUITMENT OF CONTROLS AND NEW AF PATIENT** .................. 167

**FIGURE 2 LEFT ATRIAL DILATION PARAMETERS IN CONTROLS, NEW PAF AND NEW PERAF** 168
CHAPTER FOUR..............................................................173

CHARACTERISATION OF THE INFLAMMATORY CHANGES ASSOCIATED
WITH NEW ONSET ATRIAL FIBRILLATION: IMPLICATIONS FOR INCREASED
THROMBOEMBOLIC RISK.............................................173

4.1 INTRODUCTION..............................................................173

4.2 METHODS .........................................................................174

4.2.1 Recruitment of Newly Diagnosed Atrial Fibrillation Patients ..........174

4.2.2 Recruitment of Age-matched Controls.........................................175

4.2.3 Structured Clinical Interview.....................................................176

4.2.4 Blood Collection ...................................................................176

4.2.5 Bio-markers Measured...............................................................177

4.2.6 Enzyme-Linked Immunosorbent Assay.........................................178

4.2.7 Statistical Analysis...................................................................178

4.3 RESULTS.............................................................................179

4.3.1 Baseline Characteristics.............................................................179
4.3.2  *Bio-markers of Thrombogenesis* ................................................................. 179

4.3.2.1  Endothelial Dysfunction and Vascular Function ......................................... 179

4.3.2.2  Inflammatory Markers ............................................................................... 180

4.3.2.3  Extracellular Matrix (ECM) Remodeling .................................................. 180

4.4  DISCUSSION ........................................................................................................... 180

4.4.1  *Endothelial Dysfunction and Vascular Function* ........................................ 181

4.4.2  *Inflammation* .............................................................................................. 182

4.4.3  *ECM Remodeling* ...................................................................................... 184

4.5  CLINICAL IMPLICATIONS .................................................................................. 185

4.6  LIMITATIONS ....................................................................................................... 185

4.7  CONCLUSIONS ...................................................................................................... 186

4.8  FIGURES ................................................................................................................ 187

FIGURE 1 RECRUITMENT OF CONTROLS AND NEW AF PATIENTS ...................... 187

FIGURE 2 ENDOTHELIAL DYSFUNCTION AND VASCULAR FUNCTION MEASURES IN CONTROLS AND NEW AF ........................................................................................................ 188

FIGURE 3 MARKERS OF INFLAMMATION IN CONTROLS AND NEW AF ............... 189

4.9  TABLES ................................................................................................................... 191

TABLE 1 BASELINE CHARACTERISTICS OF THE CONTROLS COMPARED TO AF PATIENTS ......................................................................................................................... 191

CHAPTER FIVE .............................................................................................................. 192

PREDICTORS AND APPROPRIATENESS OF HOSPITALISATIONS IN

PATIENTS WITH ACUTE ATRIAL FIBRILLATION ........................................... 192

5.1  INTRODUCTION ..................................................................................................... 192
CHAPTER SIX

INCIDENCE AND PREDICTORS OF REHOSPITALISATION IN PATIENTS PRESENTING TO HOSPITAL WITH ATRIAL FIBRILLATION

6.1 INTRODUCTION

6.2 METHODS

6.2.1 Study Design and Sample

6.2.2 Data Abstraction

6.2.3 Medication Profile

6.2.4 Acute Presentation Characteristics and Management Strategies

6.2.5 Follow-up

6.2.6 Statistical Analysis

6.3 RESULTS

6.3.1 Patient Sample

6.3.2 Baseline Characteristics

6.3.3 Burden of Readmissions

6.3.4 Primary Reasons for Readmissions

6.3.5 Predictors of All-cause Readmissions to Hospital

6.3.6 Predictors of Atrial Fibrillation Readmissions
ETHICS APPROVALS FOR CHAPTERS 3 & 4 ................................................................. 256

ETHICS APPROVAL FOR CHAPTERS 5 & 6............................................................... 257

ETHICAL ISSUES: ................................................................................................... 258

CHAPTER NINE........................................................................................................ 259

REFERENCES ........................................................................................................ 259
Abstract

The rising global incidence and prevalence of atrial fibrillation (AF) imposes significant burden on health care systems. Recently, several novel risk factors for AF have been identified. However, there remains a need to understand the differential impact of more established predisposing factors for incident AF. Further, there is insufficient knowledge surrounding the atrial changes that occur at the advent of AF and how this arrhythmia is managed on presentation to health care facilities. This thesis seeks to improve our understanding of the risk factors associated with this arrhythmia; to characterise any detrimental changes that occur upon its onset and to identify the AF patients that are most likely to significantly burden the hospital system. To this effect, the focus of each of the chapters is presented forthwith.

Chapter 2 focuses on the independent risk factors for incident non-valvular AF via a systematic literature review and meta-analysis. This study provides the absolute and independent effect of each established risk factor on AF development and estimates the proportion of AF cases that could potentially be prevented if modifiable risk factors were targeted at the population level.

Chapters 3 and 4 characterise the entity of newly diagnosed AF. Chapter 3 determines the existence of structural and electrical remodelling that may be present at an early stage of this arrhythmias’ evolution. Detrimental changes were found in the form of electrical substrate in paroxysmal new AF and structural substrate in persistent new AF. Chapter 4 examines the thrombogenic risk associated with new onset AF. This study shows the existence of elevated levels of pro-thrombotic bio-markers and
emphasises the need for appropriate anti-coagulation at this early stage of the AF disease process.

Chapters 5 and 6 focus on the burden that AF confers upon the hospital system by way of hospital admissions and readmissions. Chapter 5 identifies the predictors of hospital admission for AF patients presenting via the emergency department and moreover determines if all admissions are medically warranted. This study ascertained that AF patients presenting with congestive heart failure and a concurrent infection were significantly likely to be admitted to hospital for treatment and a significant proportion of patients who were admitted were low-risk AF and admission was not medically justified. This highlights a need for new management strategies in order to prevent unnecessary hospital admissions.

Lastly, chapter 6 examines the factors that increase the likelihood of readmission to hospital among AF patients. The findings showed that a substantial number of patients with index presentation for AF were readmitted to hospital. Patients who were younger and discharged on rhythm control medications were more likely to burden the hospital system with frequent AF readmissions. This study stressed the need for specialised outpatient clinics and educational interventions that could potentially reduce the increasing numbers of AF patients re-presenting to hospital.
Declaration

I certify that this work contains no material, which has been accepted for the award of any other degree or diploma in any university or other tertiary institution. To the best of my knowledge and belief, it contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this will, in the future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the explicit permission of the University of Adelaide and if applicable, any other partner institution.

I give consent to this copy of my thesis, when deposited in the University of Adelaide Library, being made available for loan and photocopying, subject to the Copyright Act of 1968.

Additionally, I give permission for the digital version of my thesis to be available on the web, via the University’s digital search repository, the Australian Digital Thesis Program (ADTP), the Library catalogue and through web search engines, unless permission has been granted by the University to restrict access for a certain period of time.

Geetanjali Rangnekar

August 2014
Acknowledgements

I would like to thank Professor Prashanthan Sanders, my primary supervisor, for his guidance and support during my doctoral degree. His enthusiasm and constant innovation has been and continues to be inspirational. I would also like to thank my co-supervisor Dr Kurt-Roberts Thomson for his help and encouragement during my studies. Special thanks to my co-supervisors, Dr. Anthony Brooks for guidance provided during the study design and execution phase and for assistance with SPSS; Dr. Scott Willoughby for assistance with the new AF studies and to Dr. Dennis Lau for his patience, assistance and guidance during thesis preparation.

I would like to thank the cardiology fellows at the Centre for Heart Rhythm Disorders for their feedback and encouragement. I have enjoyed and will cherish my time working alongside my fellow PhD candidates at the Centre for Heart Rhythm Disorders: Carlee Schultz, Melissa Neo, Wei Wen Lim. In particular, thank-you to Carlee Schultz for her help during the new AF studies. I would also like to acknowledge the staff at the Cardiovascular Centre, past and present, who helped and accommodated me during the conduction of my PhD studies; Michelle Sanders, Melissa Middledorp, Aimie Paukner, Rebecca Leinonen, Sharon King, Elena Panciewicz, Lorraine Lee, Emily Rasheed and Julia Kim.

Last but not least, I would like to say a huge thank you to my amazing family; parents, sister, brother in law, aunt, uncle, and cousins; without whose unwavering understanding, encouragement and love this PhD would have not been possible. Thank you to my wonderful friends for their unstinting fortitude, humour and love which got me through some of the most trying times.
Communications to Learned Societies

Chapter Two

1. **Presentation:** Presented at The Australian Society for Medical Research South Australian Annual Scientific Meeting, May 2014, Adelaide, Australia.

Chapter Three

1. **Presentation:** Presented at the 59th Cardiac Society of Australia and New Zealand the Scientific Meeting, August 2011, Perth, Australia and published in abstract form (Heart, Lung and Circulation 2011, 20:S105).

2. **Presentation:** Presented at the Heart Rhythm Society 33rd Annual Scientific Sessions, May 2012, Boston, United States of America and published in abstract form (Heart Rhythm 2012, 9:5, S7).

3. **Presentation:** Presented at the 60th Cardiac Society of Australia and New Zealand the Scientific Meeting, August 2012, Brisbane, Australia and published in abstract form (Heart, Lung and Circulation 2012, 21:S104-5).


5. **Presentation:** Presented at the Heart Rhythm Society 34th Annual Scientific Sessions, May 2013, Denver, United States of America and published in abstract form (Heart Rhythm 2013, 10:5, S218).

6. **Presentation:** Presented at Heart Foundation National Conference, May 2013, Adelaide, Australia.
7. **Presentation:** Presented at the 61st Cardiac Society of Australia and New Zealand the Scientific Meeting, August 2013, Gold Coast, Australia and published in abstract form (Heart, Lung and Circulation 2013, 22:S102).

**Chapter Four**

1. **Presentation:** Presented at the Heart Rhythm Society 34th Annual Scientific Sessions, May 2013, Denver, United States of America and published in abstract form (Heart Rhythm 2013, 10:5, S1).

2. **Presentation:** Presented at Heart Foundation National Conference, May 2013, Adelaide, Australia.

3. **Presentation:** Presented at the 61st Cardiac Society of Australia and New Zealand the Scientific Meeting, August 2013, Gold Coast, Australia and published in abstract form (Heart, Lung and Circulation 2013, 22:S97-98).


**Chapter Five**

1. **Presentation:** Presented at The Australian Society for Medical Research South Australian Annual Scientific Meeting, May 2014, Adelaide, Australia.

**Chapter Six**

2. **Presentation:** Presented at the 60th Cardiac Society of Australia and New Zealand the Scientific Meeting, August 2012, Brisbane, Australia and published in abstract form (Heart, Lung and Circulation 2013, 21:S107-8).

3. **Presentation:** Presented at the School of Medicine Postgraduate Research Conference, August 2012, Adelaide, Australia.

Prizes and Awards During Candidature

1. Best poster presentation (PhD) Award, Australian Society for Medical Research (ASMR), South Australian Scientific Meeting, 2014.

2. Best Poster Prize, The University of Adelaide, Faculty of Health Sciences, Department of Medicine, Postgraduate Research Conference, 2012.